Evidence map›Paper›PMID 38456228›Full record

ArticleNeuro-oncology2024

Long non-coding RNA lung cancer-associated transcript-1 promotes glioblastoma progression by enhancing Hypoxia-inducible factor 1 alpha activity.

Haidong Huang, Hariti Shah, Jing Hao, Jianhong Lin, Richard A Prayson, Liangqi Xie, Shideng Bao, Abhishek A Chakraborty, Eckhard Jankowsky, Jianjun Zhao and 1 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Haidong HuangDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Hariti ShahDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jing HaoDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jianhong LinDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Richard A PraysonDepartment of Anatomic Pathology, The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Liangqi XieDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Shideng BaoDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abhishek A ChakrabortyDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Eckhard JankowskyCenter for RNA Science and Therapeutics and Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Jianjun ZhaoDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Jennifer S YuDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Funding

lncRNA regulation of glioblastoma progression and therapeutic resistanceR01NS124081 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI Jennifer S Yu, Jianjun Zhao · 2022 to 2026
$2.7M
Visium spatial transcriptome analysis add on to the current proposed scRNA seq analysisR01CA251141 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ZHAO, JIANJUN · 2021 to 2025
$2.7M
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1R01NS092641 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI YU, JENNIFER S · 2016 to 2020
$1.7M
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through VasorinR01NS094199 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI YU, JENNIFER S · 2015 to 2019
$1.7M
Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in GlioblastomaR01NS130798 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI Jennifer S Yu · 2023 to 2026
$1.6M
NCI NIH HHS R01 CA251141NIH/NCI R01CA251141NIH/NINDS R01NS094199NINDS NIH HHS R01 NS092641NINDS NIH HHS R01 NS094199NINDS NIH HHS R01 NS124081NINDS NIH HHS R01 NS130798
6 · The paper itself

Abstract

backgroundHypoxia is associated with poor prognosis in many cancers including glioblastoma (GBM). Glioma stem-like cells (GSCs) often reside in hypoxic regions and serve as reservoirs for disease progression. Long non-coding RNAs (lncRNAs) have been implicated in GBM. However, the lncRNAs that modulate GSC adaptations to hypoxia are poorly understood. Identification of these lncRNAs may provide new therapeutic strategies to target GSCs under hypoxia.

methodslncRNAs induced by hypoxia in GSCs were identified by RNA-seq. Lung cancer-associated transcript-1 (LUCAT1) expression was assessed by qPCR, RNA-seq, Northern blot, single molecule FISH in GSCs, and interrogated in IvyGAP, The Cancer Genome Atlas, and CGGA databases. LUCAT1 was depleted by shRNA, CRISPR/Cas9, and CRISPR/Cas13d. RNA-seq, Western blot, immunohistochemistry, co-IP, ChIP, ChIP-seq, RNA immunoprecipitation, and proximity ligation assay were performed to investigate mechanisms of action of LUCAT1. GSC viability, limiting dilution assay, and tumorigenic potential in orthotopic GBM xenograft models were performed to assess the functional consequences of depleting LUCAT1.

resultsA new isoform of Lucat1 is induced by Hypoxia inducible factor 1 alpha (HIF1α) and Nuclear factor erythroid 2-related factor 2 (NRF2) in GSCs under hypoxia. LUCAT1 is highly expressed in hypoxic regions in GBM. Mechanistically, LUCAT1 formed a complex with HIF1α and its co-activator CBP to regulate HIF1α target gene expression and GSC adaptation to hypoxia. Depletion of LUCAT1 impaired GSC self-renewal. Silencing LUCAT1 decreased tumor growth and prolonged mouse survival in GBM xenograft models.

conclusionsA HIF1α-LUCAT1 axis forms a positive feedback loop to amplify HIF1α signaling in GSCs under hypoxia. LUCAT1 promotes GSC self-renewal and GBM tumor growth. LUCAT1 is a potential therapeutic target in GBM.

Indexed as

Brain NeoplasmsGene Expression Regulation, NeoplasticGlioblastomaHypoxia-Inducible Factor 1, alpha SubunitRNA, Long NoncodingAnimalsApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationDisease ProgressionHumansMiceMice, NudeNeoplastic Stem CellsPrognosisBiomarkers, TumorHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitRNA, Long Noncodingglioma stem-like cellsHIF1αhypoxialncRNALUCAT1

Identifiers

PMID38456228
PMCPMC11300024

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.